Table 4.
Effects of chemotherapy regimens in patients with active diseases
| Regimen | n | Response, n (%) | Toxicity, n (%) | EBV-DNA change, n (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematological | Nonhematological | |||||||||||||
| Overall | PR | CR | vCR | PD | SD | NA | ≥Grade 4 | NA | ≥Grade 3 | NA | <0.1 | NA | ||
| Cooling | 35 | 20 (57) | 14 (40) | 6 (17) | 0 (0) | 8 (23) | 3 (9) | 4 (11) | 8 (23) | 7 (20) | 4 (11) | 7 (20) | 1 (3) | 10 (29) |
| Steroid+CsA | 10 | 3 (30) | 1 (10) | 2 (20) | 0 (0) | 3 (30) | 3 (30) | 1 (10) | 1 (10) | 3 (30) | 0 (0) | 3 (30) | 0 (0) | 6 (60) |
| Steroid | 8 | 2 (25) | 2 (25) | 0 (0) | 0 (0) | 2 (25) | 3 (38) | 1 (13) | 1 (13) | 1 (13) | 2 (25) | 1 (13) | 1 (13) | 1 (13) |
| Steroid+ETP | 6 | 3 (50) | 3 (50) | 0 (0) | 0 (0) | 1 (17) | 2 (33) | 0 (0) | 5 (83) | 0 (0) | 4 (67) | 0 (0) | 0 (0) | 3 (50) |
| CHOP | 23 | 9 (39) | 6 (26) | 3 (13) | 0 (0) | 4 (17) | 7 (30) | 3 (13) | 17 (74) | 2 (9) | 4 (17) | 1 (4) | 2 (9) | 7 (30) |
| ESCAP | 7 | 1 (14) | 0 (0) | 1 (14) | 0 (0) | 1 (14) | 4 (57) | 1 (14) | 6 (86) | 0 (0) | 2 (29) | 0 (0) | 2 (29) | 0 (0) |
| DeVIC | 10 | 3 (30) | 2 (20) | 1 (10) | 0 (0) | 3 (30) | 4 (40) | 0 (0) | 8 (80) | 0 (0) | 1 (10) | 1 (10) | 0 (0) | 2 (20) |
| L-Asp | 5 | 3 (60) | 3 (60) | 0 (0) | 0 (0) | 1 (20) | 1 (20) | 0 (0) | 1 (20) | 0 (0) | 2 (40) | 0 (0) | 0 (0) | 1 (20) |
Data are the number of patients classified in each response category (% of persons in the regimen group).
CR, complete response; NA, not applicable; PR, partial response; PD, progressive disease; SD, stable disease; vCR, virological complete response.